Sunitinib in Patients with Metastatic Renal Cell Carcinoma with Favorable Risk: Be Aware of PD-L1 Expression.

Med Sci (Basel) · 2024 · PMC11417775 · PMID 39311161

Europe PMC DOI

hedged sentence

0.0670

closest p · 1.3× alpha

0.0670

boldest claim

The sentences

showed a trendp = 0.067so close (0.05 < p ≤ 0.1)

In the CLEAR study, patients with CPS < 1 showed a trend towards a longer PFS in the sunitinib arm ( p = 0.067) [ 12 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.